Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 in pediatric moderate to severe ulcerative colitis
NCT01585155Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Feb 2012
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in ulcerative colitis (UC), sponsored by Mitsubishi Tanabe Pharma. Started Feb 2012; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01585155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585155.